<div class="discover-view disease-state-a study-design-a1-bg view progress-full">

 <!--
<div class="home-btn nav-button loads-page">
	<span>
		<img src="images/incyte-home-btn.png" alt="HOME" title="HOME">
	</span>
</div>
-->
<div class="goback-btn nav-button develop loads-page" data-pagelink="develop" style="display: absolute">
<!--<div class="goback-btn nav-button home-btn" style="display: absolute">-->
	<span>
		<img src="images/ashe-incyte-back-btn.png" alt="Back" title="Back">
	</span>
</div>
	<div class="container-fluid sd-main">
		<h2 class="text-center">Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of INCB054828 (FGFR Inhibitor)<br>
								 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma (Including<br>
								  Fibroblast Growth Factor Receptor 2 Translocations) Who Failed Previous Therapy
		</h2>
		<div class="col-xs-3 text-center">
			<div class="col-xs-12 study-rationale-nav modal-show2" href="images/study-rationale/Incyte ASCO 2017 TS mockup INC-1244 54828-202 fight-202 (cholangiocarcinoma).jpg">
				<h4 class="absolute-center"><img src="images/people-icon.png"><br>STUDY RATIONALE</h4>
			</div>
			<div class="col-xs-12 bg-blue primary-objectives-nav7">
				<h4 class="absolute-center"><img src="images/ash-incyte-check-blue.png"><br>STUDY OBJECTIVES</h4>
			</div>
			<div class="col-xs-12 study-design-nav7">
				<h4 class="absolute-center"><img src="images/ash-incyte-pencil-blue.png"><br>STUDY DESIGN</h4>
			</div>
			<div class="col-xs-12 criteria-nav7">
				<h4 class="absolute-center"><img src="images/ash-incyte-key-blue.png"><br>KEY INCLUSION &amp;
				<br>EXCLUSION CRITERIA</h4>
			</div>
		</div>

		<!-- PRIMARY OBJECTIVES -->
		<div class="col-xs-9 primary-obj">
			<div class="chevron-container top">
				<img class="chevron-top7" src="images/ashe-incyte-chevron.png">
			</div>

			<div class="sd-main-content7">
				<!-- section 1 -->
				<div class="scroll-wrapper" style="position: relative;">
					<div id="po7">
						<div class="absolute-cen">
						<h3>Primary objective:</h3>
							<ul>
								<li>Evaluate efficacy</li>
							</ul>
						<br>
						<h3>secondary objectives:</h3>
							<ul>
								<li>Evaluate efficacy in subjects with different molecular subgroups</li>
								<li>Evaluate safety</li>
							</ul>
						</div>
					</div>
					<!-- section 2 -->
					<div id="sd7">
						<div class="absolute-cen">
						<h3>Study Design</h3>
						<img class="img-responsive" src="images/study-design/INCB054828_study_design_chart_2.png">
						<hr>
<!-- 						<p class="tiny-text">The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p> -->
						</div>
					</div>
					
					<!-- section 3 -->
					<div id="kiec7">
						<div class="absolute-cen">
						<h3>Select inclusion criteria:</h3>
						<ul>
							<li>Age ≥18 years</li>
							<li>Histologically or cytologically confirmed cholangiocarcinoma with radiographically measurable/evaluable disease per RECIST v.1.1 and disease progression after ≥1 line of prior systemic therapy</li>
							<li>Documented disease progression after at least 1 line of prior systemic therapy</li>
							<li>Eastern Cooperative Oncology Group performance status 0 to 2</li>
						</ul>
						<br>
						<h3>Select exclusion criteria:</h3>
						<ul>
							<li>Prior receipt of selective FGFR inhibitor</li>
							<li>Untreated or progressive brain or central nervous system metastases</li>
							<li>History and/or current evidence of ectopic mineralization/calcification</li>
							<li>Current evidence of corneal disorder/keratopathy confirmed by ophthalmologic examination</li>
						</ul>
						</div>
					</div>
				</div>
			</div>

			<div class="liaison-box">
				<h6>To learn if any of your patients might be eligible for participation in these studies or to learn more about becoming an investigator, please speak with one of our Medical Science Liaisons.</h6>
				<p>The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p>
			</div>

			<div class="chevron-container btm">
				<img class="chevron-btm7" src="images/ashe-incyte-chevron.png">
			</div>
		</div>
	</div>

	<div class="container-fluid text-center absolute-bottom">
		<div class="video-on">
			<div class="col-xs-12">
				<div class="col-xs-offset-11 col-xs-1">
			   		<img class="popup-btn" src="images/ashe-incyte-popup-btn.png">
			    </div>
			</div>
	    </div>
	</div>
	<!--<div class="develop-code">INC-1200e</div> -->
</div>


<div class="pop-up-div studydesign">
	<p>DCR = disease control rate, DOR = duration of response, FGF = fibroblast growth factor, FGFR = fibroblast growth factor receptor, FIGHT = Fibroblast Growth Factor Receptor Inhibitor in Oncology and Hematology Trials, ORR = objective response rate, OS = overall survival, PFS = progression-free survival,RECIST = Response Evaluation Criteria in Solid Tumors</p>
</div>